Not finding it? Sign in to also search OpenAlex live.
-
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab2020 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access
Austin Gladston Kulasekararaj, Anita Hill, Saskia M. C. Langemeijer, Richard A. Wells, Fernando Ataúlfo González Fernández, Anna Gayà, +12 more
36citations -
Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study
Régis Peffault de Latour, Alexander Roeth, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yasutaka Ueda, Carlos M. de Castro, +15 more
23citations -
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life2022 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Flore Sicre de Fontbrune, Pascale Burmester, Maria Piggin, Joana Matos, Halley Costantino, +7 more
38citations -
Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies2025 Annals of Hematology article Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Bing Han, Jaroslav Čermák, Fernando Ataúlfo González Fernández, Akihiko Gotoh, Austin Gladston Kulasekararaj, +10 more
1citations -
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors2025 The Lancet Haematology article Immunology and Microbiology Complement system in diseases Open access
Antonio Maria Risitano, Austin Gladston Kulasekararaj, Phillip Scheinberg, Alexander Röth, Bing Han, Jaroslaw Pawel Maciejewski, +47 more
16citations -
S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
Antonio Maria Risitano, Alexander Röth, Austin Gladston Kulasekararaj, Phillip Scheinberg, Yutaka Ueda, Eros Di Bona, +28 more
2citations -
Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria2025 British Journal of Clinical Pharmacology article Immunology and Microbiology Complement system in diseases Open access
Valérie F. Cosson, Rong Fu, Austin Gladston Kulasekararaj, Jun‐ichi Nishimura, Jens Panse, Alexander Röth, +14 more
10citations -
Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors
Jens Panse, Nicolas Daguindau, Sonia Okuyama, Régis Peffault de Latour, Philippe Schafhausen, Nicole Straetmans, +3 more
3citations
17 results